)
Visual24 Oct 2025
The rise of Alphabet
Sarepta Therapeutics (SRPT) investor relations material
Sarepta Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary6 Aug, 2025
Executive summary
Q2 2025 total revenues rose 68% year-over-year to $611.1M, driven by expanded ELEVIDYS sales and milestone payments from Roche.
Net income for Q2 2025 was $196.9M, a significant increase from $6.5M in Q2 2024, reflecting strong product and collaboration revenue.
Strategic restructuring announced in July 2025 targets over $100M in cost savings by end of 2025 and $400M annually from 2026, including a 36% workforce reduction and pipeline reprioritization.
ELEVIDYS shipments to non-ambulatory patients were suspended in June 2025 due to safety events; shipments for ambulatory patients resumed in late July after FDA review.
The company maintains strong liquidity, with $850.3M in cash, cash equivalents, restricted cash, and investments as of June 30, 2025.
Financial highlights
Q2 2025 product revenues increased 42% year-over-year to $513.1M, with ELEVIDYS contributing $281.9M.
Collaboration and other revenues surged to $98.0M in Q2 2025, mainly from a $63.5M milestone payment for ELEVIDYS approval in Japan.
Operating income for Q2 2025 was $115.6M, compared to a loss of $0.7M in Q2 2024; non-GAAP operating income was $162.8M, up 181% year-over-year.
For the six months ended June 30, 2025, total revenues were $1.36B, up 75% year-over-year; net loss was $250.6M, impacted by $583.6M in acquired in-process R&D expense.
Gross margin declined due to higher cost of sales, including increased inventory costs and write-offs, and higher royalties.
Outlook and guidance
Management expects current cash and investments, along with future inflows, to fund operations for at least the next twelve months.
Restructuring and cost savings initiatives are expected to strengthen liquidity and support repayment of 2027 convertible notes.
The company is evaluating the financial impact of the One Big Beautiful Bill Act and the LGMD clinical hold on future results.
Focus remains on high-impact programs, especially siRNA, with key data readouts anticipated in late 2025 and early 2026.
Ongoing collaboration with FDA to expand ELEVIDYS access to non-ambulatory Duchenne patients.
How will Sarepta mitigate ELEVIDYS liver injury risk?
Assess siRNA platform's impact on 2027 notes.
Why did cash decrease from Dec 2024 to June 2025?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Sarepta Therapeutics earnings date
Q3 20255 Nov, 2025
Next Sarepta Therapeutics earnings date
Q3 20255 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Sarepta Therapeutics Inc. is a biopharmaceutical company focused on developing genetic medicines for the treatment of rare diseases. The company specializes in RNA-targeted therapies, gene therapy, and gene editing technologies to address neuromuscular and other genetic disorders. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage